Drug intelligence / Profile preview

OMV-C-C

Development stage: Preclinical
Modality: Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Nanoparticles → Drug Delivery Systems, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous

Overview

OMV-C-C is a biosynthetically engineered bacterial outer membrane vesicle (OMV) derived from *Escherichia coli* designed for the treatment of glioblastoma (GBM). It is genetically modified to co-express cell-penetrating peptides (CPP) and chlorotoxin (CLT) on its surface, which enables the vesicle to efficiently cross the blood-brain barrier (BBB) and specifically target tumor cells. The therapeutic mechanism involves the intrinsic immunomodulatory activity of the OMV, which enhances the infiltration of CD8+ T cells into the tumor microenvironment. These T cells release interferon-gamma (IFN-γ), which subsequently induces ferroptosis in tumor cells by inhibiting the cystine-glutamate exchanger (system Xc-) and downregulating glutathione peroxidase 4 (GPX4). OMV-C-C can also serve as a delivery platform for ferroptosis inducers like RSL-3 to synergistically suppress tumor growth, offering a versatile approach to overcoming immune resistance and physiological barriers in brain tumor immunotherapy.

Other names: engineered bacterial outer membrane vesicle OMV-C-C

Targets

GPX4 (Glutathione peroxidase 4)SLC7A11 (Cystine-Glutamate Antiporter)

Beyond the preview

Go deeper on OMV-C-C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OMV-C-C.

Explore the full profile